Download the Free Prime PubMed App to your smartphone or tablet.

Available for iPhone or iPad:

Unbound PubMed app for iOS iPhone iPadAlso Available:
Unbound PubMed app for Android

Available for Mac and Windows Desktops and laptops:

Unbound PubMed app for WindowsUnbound PubMed app for MAC OS Yosemite Macbook Air pro
(Current opinion in organ transplantation[TA])
999 results
  • Donor-derived exosomes: the trick behind the semidirect pathway of allorecognition. [Journal Article]
  • COCurr Opin Organ Transplant 2016 Nov 24
  • Morelli AE, Bracamonte-Baran W, Burlingham WJ
  • CONCLUSIONS: Acquisition by recipient APCs of donor exosomes (and likely other extracellular vesicles) released by passenger leukocytes or the graft explains the potent T-cell allosensitization against donor MHC molecules, in the absence or presence of few passenger leukocytes in lymphoid organs. It also provides the basic mechanism and in-vivo relevance of the elusive semidirect pathway. Its degree of coordination with the allopeptide - specific, indirect pathway of T-cell help may determine whether semidirect allopresentation results in a sustained, effective, acute rejection response, or rather, in abortive acute rejection and 'split' tolerance.
  • Recent advances in allograft vasculopathy. [Journal Article]
  • COCurr Opin Organ Transplant 2016 Nov 24
  • Merola J, Jane-Wit DD, Pober JS
  • CONCLUSIONS: Allograft vasculopathy is a disorder resulting from several innate and adaptive alloimmune responses. Mechanistic insights from preclinical studies have identified agents that are currently being investigated in clinical trials.
  • Mechanisms of graft rejection after lung transplantation. [Journal Article]
  • COCurr Opin Organ Transplant 2016 Nov 17
  • Hsiao HM, Scozzi D, … Kreisel D
  • CONCLUSIONS: This review highlights interactions between innate and adaptive immune pathways and how they contribute to lung allograft rejection. These findings lay a foundation for the design of new therapeutic strategies that target both innate and adaptive immune responses.
  • Making new kidneys: On the road from science fiction to science fact. [Journal Article]
  • COCurr Opin Organ Transplant 2016; 21(6):574-580
  • Volovelsky O, Kopan R
  • CONCLUSIONS: Basic research into the development of metanephric kidneys and iPSC differentiation protocols, the therapeutic use of iPSCs, along with emergence of new technologies such as CRISPR/Cas9 genome editing have accelerated a trend that may prove transformative in the treatment of ESRD and congenital kidney disorders.
  • Mesenchymal stem cells to promote islet transplant survival. [Journal Article]
  • COCurr Opin Organ Transplant 2016; 21(6):568-573
  • English K
  • CONCLUSIONS: The discovery of biomarkers associated with MSC therapeutic efficacy represents an important step forward for the utilization of MSC therapy in islet transplantation; however, much remains to be elucidated about the mechanisms utilized by MSC in protection against transplanted islet loss, autoimmune-mediated and alloimmune-mediated rejection.
  • Mesenchymal stem cell therapy to promote corneal allograft survival: current status and pathway to clinical translation. [Journal Article]
  • COCurr Opin Organ Transplant 2016; 21(6):559-567
  • Murphy N, Lynch K, … Ritter T
  • CONCLUSIONS: MSCs have shown the potential to modulate corneal allograft rejection in various models using MSCs from different species. In particular for high-risk patients with poor prognosis MSC therapy might be a promising approach to promote corneal allograft survival. First-in-man clinical trials with MSC will hopefully shed new light on MSC-mediated immunomodulation in vivo and contribute to the restoration of vision in patients receiving corneal allografts.
New Search Next